-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Benzinga·05/27/2026 13:34:14
Listen to the news
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.